Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12378435 | 0.93 | ADRB1 (0.55) | ADRB1HTR2AHTR2BSIGMAR1TDP1 | |
| SCHEMBL12378451 | 0.93 | ADRB1 (0.55) | ADRB1HTR2AHTR2BSIGMAR1TDP1 | |
| SCHEMBL904556 | 0.93 | ADRB1 (0.55) | ADRB1HTR2AHTR2BSIGMAR1TDP1 | |
| SCHEMBL2288329 | 0.92 | ADRB1 (0.52) | ADRB1HTR2AHTR2BSIGMAR1TDP1 | |
| SCHEMBL14015916 | 0.89 | ADRB1 (0.49) | ADRB1HTR2AHTR2BSIGMAR1MEN1 | |
| SCHEMBL2294705 | 0.85 | ADRB1 (0.60) | ADRB1HTR2AHTR2BSIGMAR1TDP1 | |
| SCHEMBL2295494 | 0.85 | ADRB1 (0.72) | ADRB1HTR2AHTR2BSIGMAR1TDP1 | |
| SCHEMBL15267276 | 0.85 | ADRB1 (0.72) | ADRB1HTR2AHTR2BSIGMAR1TDP1 | |
| SCHEMBL12378446 | 0.85 | ADRB1 (0.72) | ADRB1HTR2AHTR2BSIGMAR1TDP1 | |
| SCHEMBL2287326 | 0.84 | GFER (0.47) | ADRB1HTR2AHTR2BSIGMAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901116-B2 | Method for treating pain, anxiety or depression using carbamoyloxy alkanoyl piperazine compound | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-12-02 | — | — | US | disclosed |
| US-8901116-B2 | Method for treating pain, anxiety or depression using carbamoyloxy alkanoyl piperazine compound | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-12-02 | — | — | US | disclosed |
| US-20140088095-A1 | METHOD FOR TREATING PAIN, ANXIETY OR DEPRESSION USING CARBAMOYLOXY ALKANOYL PIPERAZINE COMPOUND | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-03-27 | — | — | US | disclosed |
| US-20140088095-A1 | METHOD FOR TREATING PAIN, ANXIETY OR DEPRESSION USING CARBAMOYLOXY ALKANOYL PIPERAZINE COMPOUND | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-03-27 | — | — | US | disclosed |
| US-8541409-B2 | Carbamoyloxy arylalkanoyl arylpiperazine analgesics | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-09-24 | — | — | US | disclosed |
| US-8541409-B2 | Carbamoyloxy arylalkanoyl arylpiperazine analgesics | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-09-24 | — | — | US | disclosed |
| US-20110195963-A1 | NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2011-08-11 | — | — | US | disclosed |
| US-20110195963-A1 | NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2011-08-11 | — | — | US | disclosed |
| US-20110195963-A1 | NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2011-08-11 | — | — | US | disclosed |
| US-20100160331-A1 | NOVEL CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK HOLDINGS CO. LTD. (KR) | 2010-06-24 | — | — | US | disclosed |
| US-20100160331-A1 | NOVEL CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK HOLDINGS CO. LTD. (KR) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160331-A1 | NOVEL CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | HTR5A, OPRD1, OPRL1 | ADRB1 164/4885HTR2A 10/4885HTR2B 32/4885 |
| US-20110195963-A1 | NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | HTR5A, CNR2, CNR1 | ADRB1 212/4885HTR2A 11/4885HTR2B 28/4885 |
| US-20140088095-A1 | METHOD FOR TREATING PAIN, ANXIETY OR DEPRESSION USING CARBAMOYLOXY ALKANOYL PIPERAZINE COMPOUND | HTR5A, OPRL1, HDAC3 | ADRB1 237/4885HTR2A 26/4885HTR2B 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.